Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the GM1 Gangliosidosis Market Size Changed, over the years?
In the past years, the market size of GM1 gangliosidosis has significantly expanded. The market is set to increase from $0.51 billion in 2024 to $0.57 billion in 2025, displaying a compound annual growth rate (CAGR) of 11.4%. The historical growth can be linked to the rise in GM1 gangliosidosis patients, the expanding focus on GM1 gangliosidosis, the increased awareness of rare diseases, the growing emphasis on patient-centric research, and a heightened focus on early intervention.
How Much Will the GM1 Gangliosidosis Market Be Worth in 2029?
In the coming years, the GM1 gangliosidosis market is projected to undergo rapid expansion, with the market size expected to reach $0.87 billion in 2029, growing at a compound annual growth rate (CAGR) of 11.1%. Factors contributing to growth during this forecast period include an increased incidence of GM1 gangliosidosis, a rise in lysosomal storage disorder cases, an uptick in clinical trials, an amplified emphasis on gene therapy and editing, growth in personalised and precision medicine, and an increase in the use of genetic screening programs. Key trends for this period will be progress in gene-editing technologies, the integration of technology in healthcare, advancements in diagnostic methods, sophisticated formulations, and progress in genetic therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp
Which is the Largest Company in the GM1 Gangliosidosis Market?
Major companies operating in the GM1 gangliosidosis market are Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Sarepta Therapeutics Inc., CRISPR Therapeutics AG, REGENXBIO Inc., Passage Bio Inc., Orchard Therapeutics plc, AVROBIO Inc., uniQure N.V., GEMMA Biotherapeutics Inc., Lysogene S.A., AZAFAROS B.V., BioStrategies LC, Sio Gene Therapies Inc., Gain Therapeutics Inc., Dorphan S.A., bluebird bio Inc., Axovant Gene Therapies Ltd., SphinCS GmbH.
What Are the Main Market Drivers in the GM1 Gangliosidosis Industry?
The anticipated surge in the GM1 gangliosidosis market’s growth is attributed to the increasing implementation of gene therapy. Gene therapy is a medical technique that modifies or substitutes genes within an individual’s cells to treat or prevent illnesses. The escalating use of gene therapy is propelled by advancements in genetics, enhanced treatment results for previously incurable conditions, and a rising regulatory backing for innovative therapies. In GM1 gangliosidosis treatment, gene therapy consists of providing a functioning copy of the defective gene (GLB1) to the patient’s cells to reestablish β-galactosidase enzyme activity and decrease toxic substrate accumulation. For example, in April 2024, the American Society of Gene & Cell Therapy, a non-profit medical and scientific organization based in the US, revealed that in the fourth quarter, the phase III gene therapy clinical trials saw a 10% increment. This was the first increase in quarterly basis since the third quarter of 2022. Consequently, the flourishing use of gene therapy is propelling the expansion of the GM1 gangliosidosis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp
How Is the GM1 Gangliosidosis Market Segments Structured?
The GM1 gangliosidosis market covered in this report is segmented –
1) By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis
2) By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy
3) By End-User: Research Institutes, Hospitals, Other End-Users
Subsegments:
1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset
2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset
3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset
What Strategic Trends Are Transforming the GM1 Gangliosidosis Market?
Key players in the GM1 gangliosidosis market are strategizing on alliances to safeguard their market stance. These strategic partnerships are significant in progressing gene therapy research by integrating skills, assets, and innovative techniques to speed up research, clinical trials, and market availability. For instance, in October 2024, GEMMA Biotherapeutics Inc., an American biotech firm, entered a partnership with Oswaldo Cruz Foundation (Fiocruz), a health research organization based in Brazil, to pioneer gene therapies for rare disorders, including GM1 gangliosidosis. This agreement includes up to $100 million in funding from Fiocruz for clinical studies and production, with a goal of making these sophisticated therapies available within Brazil’s public health system. Moreover, this partnership focuses on technology migration and aims to democratize the accessibility of treatments previously reserved for affluent communities.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report
Which Global Regions Offer the Highest Growth in the GM1 Gangliosidosis Market?
North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194
This Report Delivers Insight On:
1. How big is the gm1 gangliosidosis market, and how is it changing globally?
2. Who are the major companies in the gm1 gangliosidosis market, and how are they performing?
3. What are the key opportunities and risks in the gm1 gangliosidosis market right now?
4. Which products or customer segments are growing the most in the gm1 gangliosidosis market?
5. What factors are helping or slowing down the growth of the gm1 gangliosidosis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model